Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production process needs to be simplified and optimized. The platform technology and the common production process requires adaption in reference to cost-effectiveness and promptness. Especially the factor “manufacturing cost” is the major driver for a successful market introduction and will influence the acceptance for later necessary mass vaccinations in the veterinary field.
The intent of “Plurivax” is to develop a stable production platform and an adapted high-quality process to have an effective and usable integrated best practice suitable for several veterinary vaccines.
The platform resulting from this project will be the first of its kind in veterinary application and thus opens access to a huge market.